Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2016

Pharma News, 2016

Novo Nordisk profit surges 19%; cuts revenue view
Novo Nordisk profit surges 19%; cuts revenue view
Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.
Hacking nerves can control disease
Hacking nerves can control disease
Controlling human nerve cells with electricity could treat a range of diseases including arthritis, asthma and diabetes, a new company says.
Atrial Fibrillation Market Will Peak in 2022 before Rapid Decline to $4.9 Billion by 2025, says GlobalData
Atrial Fibrillation Market Will Peak in 2022 before Rapid Decline to $4.9 Billion by 2025, says GlobalData
The atrial fibrillation market will expand from approximately $8 billion in 2015 to hit its peak of $11.
Chinese company accused of lying to FDA inspectors
Chinese company accused of lying to FDA inspectors
Most drug manufacturers respond immediately to the FDA after having their plant operations criticized in an inspection.
Japan's Astellas sells U.S. plant to CMO Avara
Japan's Astellas sells U.S. plant to CMO Avara
Japan’s Astellas has sold its U.
Venous Thromboembolism Therapeutics Market Set to Hit $3.7 Billion by 2025, says GlobalData
Venous Thromboembolism Therapeutics Market Set to Hit $3.7 Billion by 2025, says GlobalData
The therapeutics market for venous thromboembolism (VTE), a condition which comprises deep vein thrombosis and pulmonary embolism, is set to rise from $2.
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
BEVERLY, MA, USA - August 03, 2016 - Cellceutix Corporation, (CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Pfizer Inc. Wins A $40 Million Bid By BIND Therapeutics Inc
Pfizer Inc. Wins A $40 Million Bid By BIND Therapeutics Inc
Pfizer Inc.
Theranos CEO Elizabeth Holmes trades new, unproven tech for old
Theranos CEO Elizabeth Holmes trades new, unproven tech for old
Theranos CEO Elizabeth Holmes, here at a confer ence last year, is touting a new blood test, deflect ing criticism of the firm’s methods that are under investigation.
Google Parent and GlaxoSmithKline Are Creating a $715 Million Bioelectronics Firm
Google Parent and GlaxoSmithKline Are Creating a $715 Million Bioelectronics Firm
It will focus on fighting diseases by targeting electrical signals in the body.
FDA grants fast track for Shire’s NASH investigational treatment
FDA grants fast track for Shire’s NASH investigational treatment
          SHP626 (volixibat)Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixiba...
Cardiac Fibrosis: Bile Acid May Prevent Myocardial Fibrosis
Cardiac Fibrosis: Bile Acid May Prevent Myocardial Fibrosis
Tauroursodeoxycholic acid  (TUDCA)Currently there is no treatment for cardiac fibrosis, a leading cause of heart failure.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand